---
title: "Designing Orthopaedic Clinical Evidence for Europe"
description: "Orthopaedic clinical development presents distinct challenges. Outcomes depend not only on the device, but also on surgical technique, implant mechanics, patient anatomy, rehabilitation and long-term functional recovery. This whitepaper shows how early stakeholder engagement supports a robust, feasible and clinically meaningful evidence strategy for Europe."
url: https://qbdgroup.com/en/downloads/designing-orthopaedic-clinical-evidence-europe
type: "White paper"
language: en
published: 2026-09-04
author: "Laura Drikite & Caroline Aernouts"
category: "Clinical"
publisher: "QbD Group"
citation: "QbD Group, \"Designing Orthopaedic Clinical Evidence for Europe\", https://qbdgroup.com/en/downloads/designing-orthopaedic-clinical-evidence-europe"
---
# Designing Orthopaedic Clinical Evidence for Europe
> Orthopaedic clinical development presents distinct challenges. Outcomes depend not only on the device, but also on surgical technique, implant mechanics, patient anatomy, rehabilitation and long-term functional recovery. This whitepaper shows how early stakeholder engagement supports a robust, feasible and clinically meaningful evidence strategy for Europe.

<!-- meta_description: Learn why early stakeholder engagement matters in orthopaedic clinical investigation design and protocol development for the EU MDR. Download the QbD Group white paper. -->

## About this white paper

Orthopaedic clinical development presents distinct challenges. Outcomes depend not only on the device, but also on surgical technique, implant mechanics, patient anatomy and long-term functional recovery. For manufacturers targeting Europe, these complexities are compounded by the clinical evidence and post-market requirements of the EU Medical Device Regulation (MDR).

A robust evidence programme starts well before the first patient is enrolled. Pre-clinical testing — mechanical, fatigue, wear, biocompatibility, in vivo and sterilisation studies — must first show that an implant is structurally sound, biologically safe and predictable enough to progress to clinical investigation.

From there, early stakeholder engagement becomes critical. Patient groups, surgeons, clinical operations, regulatory specialists and biostatisticians each help ensure that endpoints are clinically meaningful, recruitment assumptions are realistic and the investigation can generate reliable evidence. This is especially important for non-EU manufacturers, as data accepted elsewhere may not meet European expectations.

This whitepaper examines the pre-clinical foundation of orthopaedic device development and shows how involving the right stakeholders early supports a scientifically robust, operationally feasible and clinically meaningful evidence strategy for Europe.

## Key Takeaways

- Why pre-clinical evidence must be in place before defining the clinical investigation strategy
- How device characteristics — material, design, intended lifetime and degradation profile — shape endpoints and follow-up
- When new clinical investigation data are needed and when existing evidence may be sufficient
- Which stakeholders to engage early and what each contributes to study design and protocol development
- How early alignment reduces the risk of evidence gaps, protocol amendments and resubmissions under the EU MDR
- Why long-term follow-up matters for implant survival, wear, loosening, degradation and revision surgery

## Download this white paper

Complete the form on this page to receive your copy.
---
Source: https://qbdgroup.com/en/downloads/designing-orthopaedic-clinical-evidence-europe — © QbD Group. Quote freely with attribution and a link back.